NCT07254364Recruiting
Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
Noninvasively monitoring insulin is crucial for advancing precision nutrition and promoting healthy living by enabling a deeper understanding of individual metabolic responses to dietary intake. Insulin is a key regulator of blood sugar and energy metabolism, and its dysregulation is linked to conditions such as diabetes, obesity, and metabolic syndrome. By noninvasively tracking insulin levels, individuals can gain real-time insights into how their body processes different foods, allowing for the personalization of diets to optimize metabolic health, manage weight, and reduce disease risk. This approach also empowers proactive lifestyle adjustments to maintain insulin sensitivity, improve glycemic control, and enhance overall well-being. Decentralized insulin quantification in biofluids, including saliva and serum, based on lateral flow assay or electrochemical sensor has been reported. However, these approaches have poor sensitivity and fail to quantify insulin with a high temporal resolution.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 19 Nov 2025
- Start date
- 11 Sept 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Texas A&M University
- Diseases
- Type 1 diabetes
- NCT number
- NCT07254364
What you commit to
- Study type: Interventional
- Planned participants: 32
- From 11 Sept 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active dependence on alcohol or drugs
- Use of a short course of oral corticosteroids within 4 weeks preceding study day
- Current use of long-term oral corticosteroids
- Planned elective surgery requiring 2 or more days of hospitalization during the entire study
Other illness
- Known allergy to any of the components of the meal or agents used for the application of the devices
- Sunflower oil
- Maltodextrin
- Whey protein
- Pilocarpine solutions
- Established diagnosis and active treatment of chronic disease: insulin-dependent diabetes, active malignancy, heart failure, kidney disease, liver disease, HIV/AIDS, asthma (moderate to severe), Hep (A, B, or C)
- History of untreated metabolic disease including hepatic or renal disorder
- Presence of acute illness or metabolically unstable chronic illness
- Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject
- Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
Other
- Presence of fever within the last 3 days
- (Possible) pregnancy (confirmed via urine pregnancy test for females 18-30 years)
Who the study is looking for
- Age
- ● 18-30 years old
- ● 50-90 years old
- BMI between 18 and 35 kg/m2
- Ability to walk, sit down, and stand up (independently or with a walking assistance device)
- Willingness to lay supine in bed for up to 9 hours
- Willingness and ability to comply with the protocol
Age in the registry: 18 years to 90 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Texas A&M University Coordinator of this site? Confirm its status | College Station | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.